Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical GuidelinesCOVID-19 감염 예방 및 치료를 위한 Ivermectin: 임상 지침을 제공하기 위한 체계적인 검토, 메타 분석 및 시험 순차 분석Meta-Analysis Published on 2021-06-212022-09-11 Journal: American journal of therapeutics [Category] SARS, 치료제, [키워드] 95% confidence interval adverse event Analysis anti-inflammatory properties antiparasitic Antiviral approach Area average average risk benefit certainty Chemoprophylaxis clinical Clinical course clinical trials conducted COVID-19 COVID-19 infection database death Deterioration Efficacy estimate Evidence evidence of guideline high risk Inclusion Ivermectin ivermectin treatment less mechanical ventilation Medicine meta-analyses Meta-analysis Mortality no difference outcome pandemic participant prevention Prophylaxis provided Randomized controlled trial reduce reduced reduced risk reducing mortality reductions in review Risk of bias risk ratio robust SARS-CoV-2 pandemic SARS-CoV-2 virus searched secondary secondary outcome Secondary outcomes sequential analysis severe adverse events severe disease suggested tested the SARS-CoV-2 the SARS-CoV-2 virus treatment trial treatment trials Trial trial sequential analyses trial sequential analysis [DOI] 10.1097/MJT.0000000000001402 PMC 바로가기 [Article Type] Meta-Analysis
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trialResearch article Published on 2021-06-182022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] Adverse Antiviral antiviral activity Antiviral effect baseline blinded clinical endpoint clinical evolution clinical utility Concentration Control controls correlated COVID-19 determine drug concentration evaluate event finding funding group groups High-dose hospital hospitalized patient in viral in vitro IQR Ivermectin median no difference participant Patient patients with COVID-19 plasma plasma concentration primary endpoint Quantitative Randomized randomized trial recruited reduction regimen Registered RT-PCR SARS-CoV-2 SARS-COV-2 infection secretion shown significant difference Standard of care supported symptoms onset Treatment Trial Viral load were measured [DOI] 10.1016/j.eclinm.2021.100959 [Article Type] Research article
Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19경증 COVID-19의 상부 호흡기 증상을 감소시키는 Ivermectin Mucoadhesive Nanosuspension Nasal Spray의 임상, 생화학적 및 분자 평가Randomized Controlled Trial Published on 2021-06-152022-09-11 Journal: International journal of nanomedicine [Category] 임상, 치료제, [키워드] age Anosmia anti-parasitic assessment assessments biochemical biochemical and molecular biochemical parameter Biochemical parameters Blood C-reactive protein clinical clinical trial Complete complete blood counts cough COVID-19 D-dimer diagnosed dimer Duration Dyspnea effective female Fever gastrointestinal symptoms hematological in vitro inhibit SARS-CoV-2 intranasal Ivermectin ivermectin nanosuspension male Manifestations Mild nasal Nasal spray nasal spray. Nasopharyngeal swab nasopharyngeal swabs Negative PCR negativity nucleic acid Patient performed Pharyngeal swab presenting protocol Randomly Replication respiratory rRT-PCR Safe SARS-CoV-2 replication Serum ferritin shown significant difference significantly shorter spray the patient therapeutic efficacy Treatment upper viral clearance was performed [DOI] 10.2147/IJN.S313093 PMC 바로가기 [Article Type] Randomized Controlled Trial
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021Pharmacology Published on 2021-06-142022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] affected approval approved Case series China Chloroquine clinical trials Cohort studies contagious COVID-19 COVID-19 infections doxycycline drug drug candidate effective Favipiravir globe Health Hydroxychloroquine in silico approaches in vitro in vivo information investigated Ivermectin knowledge lack Lopinavir-ritonavir management meta-analyses NIH pandemic pharmacological position Preliminary data Prophylaxis protease inhibitors Remdesivir repurposing repurposing drugs researcher Retrospective study rivaroxaban Safety SARS-CoV-2 Stage Standing therapeutic option transmitted Transport Treatment Vaccines viral outbreak viral pathogenesis World Health Organization [DOI] 10.3389/fphar.2021.659577 PMC 바로가기 [Article Type] Pharmacology
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributesCOVID-19 치료를 위한 잠재적 약물로서의 Ivermectin: 임상 및 컴퓨터 속성과 동기화된 검토Review Published on 2021-06-012022-09-11 Journal: Pharmacological Reports [Category] 치료법, 치료제, [키워드] Analysis anti-parasitic drug antiviral properties approach article artificial intelligence attribute attributes can be used carried classical Classical mechanics clinical trial clinically Controlled COVID-19 COVID-19 case COVID-19 cases dose drug Drug development drugs Evidence facilitate indicate Interaction Ivermectin management molecular molecular dynamics molecular interaction N-protein N-terminal domain NTD nucleocapsid protein Numerous pharmacokinetic positive RCTs SARS-CoV 2 SARS-CoV-2 specificity Support target targets Treatment Vaccine Viral protein [DOI] 10.1007/s43440-020-00195-y PMC 바로가기 [Article Type] Review
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infectionClinical Trial Published on 2021-06-012022-10-05 Journal: Pathogens and global health [Category] 임상, [키워드] addition Admission age Antibiotics Anticoagulant approved Brazil caused Chloroquine coronavirus Corticosteroid COVID-19 death diabetes double-blind drug drugs Effectiveness Efficacy Endpoint form groups HCQ Hospital admission hospitalized patient Hydroxychloroquine ICU ICU admission incidence independent independent risk factor invasive ventilation IRB Ivermectin male manifestation Mortality no difference not reduce obesity objective Older pandemic participant Patient patients patients hospitalized performed Phase 2 Phase 2 study Physicians predictor pulmonary involvement Randomized randomized study reference Result safety profile SARS-COV-2 infection Serious Adverse Event supplemental oxygen tested three group [DOI] 10.1080/20477724.2021.1890887 PMC 바로가기 [Article Type] Clinical Trial
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon무증상 SARS-CoV-2 감염 대상의 바이러스 및 임상 결과에 대한 Ivermectin의 단일 용량 효과: 레바논의 파일럿 임상 시험Randomized Controlled Trial Published on 2021-05-262022-08-13 Journal: Viruses [Category] SARS, 임상, 치료제, [키워드] addition appear Asymptomatic asymptomatic subject asymptomatic subjects body weight both groups clinical clinical benefit clinical benefits Clinical symptoms clinical trial conducted control group Ct values Ct-value Ct-values determine Effect Efficacy experimental group FDA-approved drug Hospital admissions Hospitalization in both group increase in individual Ivermectin ivermectin group Lebanon no significant difference pandemic Patient positive preventive treatment producing Randomized Randomized controlled trial reduced regimen required resulting SARS-CoV-2 SARS-CoV2 significant difference single dose subject subjects Symptoms tested therapy Treatment Trial two group two groups Viral Viral load viral loads virus [DOI] 10.3390/v13060989 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical TrialControlled Trial Published on 2021-05-062023-06-17 Journal: Clinical therapeutics [Category] MERS, SARS, [키워드] clinical trial cough COVID-19 Dyspnea Ivermectin lymphopenia [DOI] 10.1016/j.clinthera.2021.04.007 PMC 바로가기 [Article Type] Controlled Trial
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trialRandomized Controlled Trial Published on 2021-05-012022-10-05 Journal: The Journal of international medical research [Category] SARS, 임상, [키워드] 95% confidence interval age assigned blinded clinical recovery Combination COVID-19 COVID-19 infection COVID-19 negative COVID-19 symptom disease Disease progression doxycycline Dryad enrolled evaluated Follow-up groups hazard ratio Infection Ivermectin less Median recovery time men Mild-to-moderate outcome Patient patients Placebo placebo group placebo-controlled trial polymerase chain positive Primary outcome proportion Randomized randomized trial Randomly Recovery time reduced remained Repository reverse transcription reverse transcription polymerase chain reaction RT-PCR screened secondary significantly lower the placebo group treated treating COVID-19 Treatment treatment group with COVID-19 [DOI] 10.1177/03000605211013550 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19nitazoxanide, ribavirin 및 ivermectin과 아연 보충제의 조합(MANS.NRIZ 연구)이 가벼운 COVID-19 제거에 미치는 영향Clinical Trial Published on 2021-05-012022-09-12 Journal: Journal of medical virology [Category] SARS, 임상, 진단, [키워드] age Antiviral clearance clearance rate Combination combined use confirmed case Controlled trial COVID-19 cumulative Effect groups Ivermectin Mild mild cases mild cases. Nasopharyngeal swab nasopharynx non-randomized Patient polymerase chain positive receiving ribavirin subject Supportive treatment symptomatic therapy Treatment Trial triple combination viral clearance Zinc [DOI] 10.1002/jmv.26880 PMC 바로가기 [Article Type] Clinical Trial